GeoVax to Present Pipeline Updates at H.C. Wainwright Investment Conference
GeoVax Labs will showcase progress on its Mpox/smallpox, COVID-19, and cancer immunotherapy programs at the upcoming H.C. Wainwright conference, highlighting advancements in vaccine development and manufacturing capabilities.
GeoVax Labs, Inc. announced that Chairman and CEO David Dodd will present a company overview and host investor meetings during the H.C. Wainwright 27th Annual Global Investment Conference in New York City. The presentation will cover recent progress and upcoming milestones across the company's pipeline, including three key development programs.
The company's GEO-MVA vaccine, a next-generation MVA-based Mpox/smallpox vaccine, recently received favorable Scientific Advice from the European Medicines Agency. This positions the vaccine to support global preparedness and stockpile strategies, with the company anticipating progression directly to Phase 3 clinical evaluation based on recent EMA regulatory guidance.
GeoVax will also discuss GEO-CM04S1, its multi-antigen COVID-19 vaccine currently being evaluated in three Phase 2 clinical trials across various patient populations. The trials include immunocompromised individuals and healthy adults, addressing critical gaps in vaccine coverage for vulnerable populations.
The oncology program features Gedeptin®, the company's gene-directed enzyme prodrug therapy for solid tumors, with an upcoming Phase 2 trial in head and neck cancer. This represents an important advancement in cancer immunotherapy approaches.
The company will highlight how its MVA platform and U.S.-based continuous cell line manufacturing capabilities position GeoVax to address critical gaps in vaccine supply diversification, pandemic readiness, and biosecurity. A webcast of the presentation will be available at https://journey.ct.events/view/40d09ded-caa5-44ff-baf7-10795e9d5386 beginning at 7:00 am ET on September 8, 2025.
These developments are significant as they demonstrate progress in addressing unmet medical needs in infectious disease prevention and cancer treatment, while also contributing to global health security through advanced vaccine manufacturing capabilities. The company's approach to targeting multiple disease areas with platform technologies represents an important trend in biotechnology innovation.